Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 1, 2015
Pharmacy Choice - News - Front Page Healthcare News - March 1, 2015

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/1/15 - Bills would block Tennessee health insurance exchange: Lawmakers act ahead of latest Obamacare challenge [Chattanooga Times Free Press, Tenn.]
Bill Haslam's plan to extend Medicaid to 280,000 low-income Tennesseans now is targeting 230,000 people already covered under the federal health insurance exchange. Brian Kelsey's bill would block Tennessee from creating its own state-run exchange if opponents to the Affordable Care Act, known as Obamacare, lose their latest legal challenge.
3/1/15 - Florida House, Senate priorites coincide on Amendment 1, education; differ on health care, medical marijuana [The Bradenton Herald]
Meanwhile, Senate Majority Leader Bill Galvano, R- Bradenton, says he definitely wants to look at Senate. Galvano has also called for expanding Medicaid under the Affordable Care Act, commonly known as Obamacare. Rick Scott has said he supports the expansion of Medicaid as well, but both Boyd and Steube indicate that House leadership support for ap
3/1/15 - IUD, implant contraception effective beyond FDA-approved use
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA New research indicates that hormonal intrauterine devices and contraceptive implants remain highly effective one year beyond their approved duration of use, according to a study at Washington University School of Medicine in St. Louis. The researchers are evaluating whether su
3/1/15 - Local health care providers are working to shift trends [Grand Haven Tribune, Mich.]
Feb. 28 Years before the most recent community health needs assessment, the Grand Haven- based North Ottawa Community Health System started working to bolster its primary care foundation. When the 2012 assessment indicated area residents need more access to medical care, it helped validate the health system's efforts, said NOCHS spokeswoman Jen V
3/1/15 - Researchers at University of Arizona Report Findings in Halogens (Beyond C, H, O, and N! Analysis of the elemental composition of U.S. FDA approved...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Investigators publish new report on Halogens. According to news reporting from Tucson, Arizona, by NewsRx journalists, research stated, "The diversity of elements among U.S. Food and Drug Administration approved pharmaceuticals is analyzed and reported, with a focus on atoms o
3/1/15 - Sanitarium stands to reap windfall from liver drug
Baltimore s Asklepion Pharmaceuticals which counts the New Zealand breakfast cereal maker as an investor secured an acquisition agreement with New York- based Retrophin in January. Retrophin has acquired the worldwide rights to Asklepion s colic acid treatment for a deadly genetic liver defect, provided the drug receives US Food and Dru
2/28/15 - A 'stroke initiative' [Saudi Gazette, The]
Suhail Abdulla Al-Rukn, neurology consultant and stroke specialist at the Neurology Department of Rashid Hospital in Dubai, explains the importance of the "Stroke Initiative" program at the recent launching while other participants listen.- Courtesy photo.. In the Middle East and North Africa, stroke is increasingly becoming a major health issue, w
2/28/15 - Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell...
2/28/15 - FDA Grants 7 Years' U.S. Market Exclusivity to Eagle Pharmaceuticals for Ryanodex [Professional Services Close - Up]
Eagle Pharmaceuticals confirmed that the U.S. Food and Drug Administration has granted seven years of market exclusivity in the U.S. to Ryanodex for Injectable Suspension for the treatment of malignant hyperthermia. According to a release from the company, Ryanodex was designated an orphan drug in August 2013 and was approved by the FDA in July 201
2/28/15 - Infinity Offers Company Recaps Full-Year 2014 Financial Results [Professional Services Close - Up]
Infinity Pharmaceuticals reported its full-year 2014 financial results and ongoing progress with duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase- delta and PI3K-gamma. "In 2014, Infinity continued to advance duvelisib in registration- focused studies and entered a global collaboration with AbbVie to expand and accelerate the...
2/28/15 - Ireland : ACTAVIS wants FDA approval to market generic ulcerative colitis drug [TendersInfo (India)]
Actavis, Irish specialty pharmaceutical firm entered an abbreviated new drug application to the US Food and Drug Administration want approval to market Budesonide Extended-release Tablets, 9 mg. Earlier in February 2015, Santarus and Cosmo Technologies filed a lawsuit, under provisions of the Hatch-Waxman Act, against Actavis in the US District Cou
2/28/15 - Research and Markets Offers Report: IVD Procedure Volumes and Pricing Analysis [Professional Services Close - Up]
Research and Markets has added the "IVD Procedure Volumes and Pricing Analysis" report to its offerings. In a release, Research and Markets noted that report highlights include:. Clinical laboratory medicine plays an integral role in healthcare and disease management, as it estimated that approximately 80 percent of physician's diagnoses are a resu
2/28/15 - St. Mary's hits the century mark amid the challenges of today's health care [Enid News & Eagle, Okla.]
Feb. 27 ENID, Okla. St. Mary's Regional Medical Center is focused on the future with one eye on its past. G.A. Boyle as a 12- bed facility called Enid Spring Sanatorium and Baths. Mary's chief executive officer, said an anniversary dinner is planned for this spring at Enid Event Center.
2/28/15 - United States : Amgen Announces the European Medicines Agency Acceptance of Kyprolis (carfilzomib) Marketing Authorization Application for the... [TendersInfo (India)]
Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency has accepted the Marketing Authorization Application of Kyprolis for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. Achieving deep and durable responses for patients with...
2/28/15 - VertiFlex: FDA Advisory Panel Supports PreMarket Approval Application of the Superion Interspinous Spacer [Professional Services Close - Up]
VertiFlex reported that the U.S. Food and Drug Administration's Orthopedic and Rehabilitation Devices Advisory Panel has voted strongly in support of the PreMarket Approval application for the company's Superion Interspinous Spacer System. We will continue to work closely with the FDA to complete their review of our PMA while we finalize plans for.
2/27/15 - ACORDA THERAPEUTICS INC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.
We market three FDA- approved therapies, including Ampyra Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis, or MS, as demonstrated by an increase in walking speed. In October 2014, we acquired Civitas Therapeutics, Inc., a biopharmaceutical company which is developing CVT-301, a Phase 3 treatment c
2/27/15 - Actavis and Medicines360 Announce FDA Approval of LILETTA? (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years
DUBLIN and SAN FRANCISCO, Feb. 27, 2015/ PRNewswire/ Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA? by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. Actavis and Medic
2/27/15 - Actavis Confirms Generic Uceris Patent Challenge [Professional Services Close - Up]
Actavis on February 24 confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Budesonide Extended- release Tablets, 9 mg. Cosmo Technologies Limited and Santarus, Inc. filed suit against Actavis on February 17, in the U.S. District Court for the District of Delaware seek
2/27/15 - Actavis: FDA OKs LILETTA To Prevent Pregnancy For Up To 3 Years
WASHINGTON- Actavis plc, a global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA by the U.S. Food and Drug Administration or FDA for use by women to prevent pregnancy for up to three years. Actavis and Medicines360's groundbreaking partnership would allo
2/27/15 - AIDS Foundation of Chicago complains about insurers' high drug prices [Chicago Tribune]
Several standard treatments cost more than $1,000 per month on many Coventry Health Care and Humana plans, while some of the same drugs cost as little as $35 on plans other insurers sell on the exchange, according to an AIDS Foundation of Chicago analysis. The AIDS Foundation warned Coventry, Humana and two other insurers in January letters that th
The Company has two divisions, Home Health Care and Healthcare Innovations. The Home Health Care division is comprised of two reportable segments, Visiting Nurse Services and Personal Care Services. Approximately 94% of the VN segment revenues are generated from the Medicare program while the balance is generated from Medicaid and private insurance
2/27/15 - Archroma receives FDA approval for Cartaguard KST additive [EMBIN (Emerging Markets Business Information News]
Switzerland- based color and specialty chemicals company Archroma has received FDA approval for the use of its new Cartaguard KST additive in the manufacture of paper and board for food packaging. The product has been approved by the US Federal Food and Drug Administration under 21 CFR 176.170 and can be used as a grease resistance treatment before
2/27/15 - Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix paediatric study
*Study Meets Primary Endpoint and Achieves Low Bleeding Rates with Once- Weekly Prophylactic Dosing in Children* Results Support EU Regulatory Submission and Future Paediatric Indication Applications Biogen Idec and Swedish Orphan Biovitrum AB today announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the...
2/27/15 - California Healthcare Institute Applauds Efforts to Protect FDA Budget from Sequestration [EMBIN (Emerging Markets Business Information News]
Anna G. Eshoo and Leonard J. Lance for leading the charge to protect the FDA from the serious threat of potential future user fee cuts brought on by sequestration. It would not be possible for the United States ? with California front and center ? to become the global leader in life sciences innovation, without adequate funding of FDA, incl
2/27/15 - Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
Capricor Therapeutics, Inc., a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Thomas Copmann, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs and Drug Development. In this role, Dr. Copmann will lead the company's reg
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Lupus: What You Need to Know
This lesson is supported by:
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement